Sarepta Therapeutics (NASDAQ:SRPT) is up nearly 13% in pre-market trading on a story highlighting a Duchenne Muscular Dystrophy (DMD) patient’s progress on the company’s development-stage treatment, eteplirsen. On July 24th, the company reported positive results of eteplirsen after 36 weeks of treatment in a Phase IIb study for the treatment of DMD, and 48-week results are due to be presented at the World Muscle Society Conference in mid-October. SRPT has been lifted recently by a bullish article in Barron’s last weekend, as well as a Buy rating assigned to the stock earlier this week by brokerage firm Think Equity. Expect SRPT to trade higher into the 48-week Phase IIb data, given speculation that the company could be able to submit the drug for FDA approval on the results if efficacy and safety are compelling and maintained for a longer period. DMD remains an unmet medical need.